<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RTT</z:e>) is an <z:hpo ids='HP_0001417'>X-linked</z:hpo> <z:hpo ids='HP_0002448'>progressive encephalopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Mutations in the MECP2 (<z:chebi fb="36" ids="29309">methyl</z:chebi>-CpG-binding protein) gene have been found to cause <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RTT</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In the past few years, the role of MECP2 mutations in patients with <z:e sem="disease" ids="C0004936" disease_type="Mental or Behavioral Dysfunction" abbrv="">mental disorders</z:e> other than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RTT</z:e> has been studied, finding that mutations in MECP2 also contribute to non-syndromic entities </plain></SENT>
<SENT sid="3" pm="."><plain>More recently, it has been demonstrated that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RTT</z:e> shares clinical features with those of <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e>, another <z:e sem="disease" ids="C1535926" disease_type="Mental or Behavioral Dysfunction" abbrv="">neurodevelopmental disorder</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>These observations must be confirmed in a large series, to better understand the criteria needed for justifying a molecular test </plain></SENT>
<SENT sid="5" pm="."><plain>Consequently, we have searched for MECP2 mutations in 294 patients (43 Angelman and Prader-Willi like included) with <z:hpo ids='HP_0001249'>mental retardation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) of unknown aetiology </plain></SENT>
<SENT sid="6" pm="."><plain>We found six polymorphisms (three novel, three previously reported) in 10 patients, one novel unclassified silent change (p.V222V) in a man, and one causative mutation in a girl with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Once this case was clinically reviewed, the girl presented symptoms of atypical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RTT</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The mutation (p.Y141C) lies within the <z:chebi fb="36" ids="29309">methyl</z:chebi>-binding domain, and has only been reported once in another atypical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RTT</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Our results show that the MECP2 mutations account for a low frequency (1/416 chromosomes = 0.24%) among mentally retarded individuals, which imply that it is necessary to perform an exhaustive clinical examination of patients before determining whether analysis of MECP2 is required or not </plain></SENT>
</text></document>